$OCGN
Congrats to shareholders here, and, welcome to anyone who is checking $OCGN out for the 1st time.
$OCGN - about to finish phase III trials
Fidelity previously added $OCGN to one of their index funds. And, institutionals / large investors have been block buying the HELL out of it. Zacks has $OCGN rated a SUPER BUY, with a $1.63 target:
https://www.zacks.com/stock/quote/OCGN?q=OCGN
Ocugen has at least one drug in phase 3 testing (OCU300), and several pipeline drugs:
https://ocugen.com/pipeline/ocu300/
Specifically, OCU300 was developed from another Ocugen FDA approved drug. And, was entered into an accelerated approval path (excerpt from link above):
Leveraging Ocugen’s OcuNanoE technology, OCU300 consists of a proprietary formulation of brimonidine tartrate, an FDA-approved drug with established safety for ocular use, enabling Ocugen to develop OCU300 under the accelerated 505(b)(2) regulatory pathway.
OCU300 entered FDA trials in 2018, and, is getting close to completion of phase 3 of the OCU300 trials:
Estimated Primary Completion Date :
July 2020
Estimated Study Completion Date :
August 2020
https://clinicaltrials.gov/ct2/show/NCT03591874
To reiterate, $OCGN is closing in on the completion of the OCU300 phase III trial, and OCU300 has demonstrated good topline results (re: Page 8):
https://ir.ocugen.com/static-files/f8198c96-a60e-4c55-a4c8-86b2a068f8f0
ALSO, the company just cleaned up its debt situation, while obtaining new funding. Volume has been trending up to 5X AVG on a daily basis, so, it is CLOSE.